Coya Therapeutics, Inc. 8K

Coya Therapeutics, Inc. filed a Form 8-K including a legal opinion confirming the validity of up to $30 million of common stock to be issued under a Sales Agreement with Leerink Partners LLC pursuant to its Form S-3 shelf registration.

On May 12, 2026, Coya Therapeutics, Inc. filed a Form 8-K that included a legal opinion from Lowenstein Sandler LLP as Exhibit 5.1, in which counsel opined that up to $30,000,000 of the company’s common stock to be issued pursuant to a May 12, 2026 Sales Agreement with Leerink Partners LLC, as sales agent, under the company’s Form S-3 shelf registration, have been duly authorized and, when issued and paid for in accordance with the Sales Agreement, will be validly issued, fully paid, and non-assessable under Delaware law.

Filing Facts

CIK

1835022

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-218282

Alert Tier

5